Schering contrast agent debuts in Sweden:
This article was originally published in Clinica
Executive Summary
Schering (Berlin, Germany) has gained approval for its liver specific-contrast agent, Resovist, in Sweden. Schering used the EU's mutual recognition procedure to gain the approval, which marks the worldwide marketing debut of the product. Resovist was developed in collaboration with Japan's Meito Sangyo. It will be launched in Sweden in mid-2001. The agent is injected as an intravenous bolus and can detect and characterise small liver focal lesions, enabling early detection of hepatic carcinoma or metastases. Imaging is immediate, cutting down examination time. Schering claims a 60 % share of world MRI contrast agent sales.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.